The dynamics of Dyne

How Atlas start-up Dyne plans to use nucleic acids to treat rare muscle diseases

Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1).

As it develops its own pipeline, the company could also in

Read the full 457 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE